Phosphodiesterase type 5 (PDE5) in the adipocyte: A novel player in fat metabolism?

Trends in Endocrinology and Metabolism

Volumn 22, Issue 10, 2011, Pages 404-411

  Armani, Andrea ^a   Marzolla, Vincenzo ^b   Rosano, Giuseppe M C ^a   Fabbri, Andrea ^c   Caprio, Massimiliano ^a  

^a IRCCS SAN RAFFAELE PISANA   (Italy)

^b San Raffaele Sulmona   (Italy)

^c UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC GMP; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PHOSPHODIESTERASE V;

ADIPOCYTE; BINDING AFFINITY; BIOGENESIS; CELL DIFFERENTIATION; CELL FUNCTION; CELL MATURATION; CYTOPLASM; ENZYME ACTIVITY; ENZYME BINDING; ENZYME PHOSPHORYLATION; FATTY ACID METABOLISM; GENETIC TRANSCRIPTION; HEART; HUMAN; LIPOLYSIS; LUNG; METABOLIC SYNDROME X; MITOCHONDRION; NONHUMAN; OBESITY; PANCREAS; PENIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; SPERMATOGENESIS;

ADIPOCYTES; ADIPOGENESIS; ADIPOSE TISSUE; ANIMALS; CELL DIFFERENTIATION; CYCLIC GMP; CYCLIC GMP-DEPENDENT PROTEIN KINASES; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 5; ENZYME ACTIVATION; HUMANS; INSULIN; LIPID METABOLISM; LIPOLYSIS; OBESITY; SIGNAL TRANSDUCTION;

EID: 80053098385     PISSN: 10432760     EISSN: 18793061     Source Type: Journal    
DOI: 10.1016/j.tem.2011.05.004     Document Type: Review

References (72)

1. Sethi J.K., et al. Thematic review series: adipocyte biology. Adipose tissue function and plasticity orchestrate nutritional adaptation. J. Lipid Res. 2007, 48:1253-1262.
2. Deng Y., et al. Adipokines as novel biomarkers and regulators of the metabolic syndrome. Ann. N. Y. Acad. Sci. 2010, 1212:E1-E19.
3. Grundy S.M. Obesity, metabolic syndrome, and cardiovascular disease. J. Clin. Endocrinol. Metab. 2004, 89:2595-2600.
4. Hajer G.R., et al. Adipose tissue dysfunction in obesity, diabetes, and vascular diseases. Eur. Heart J. 2008, 29:2959-2971.
5. Guilherme A., et al. Adipocyte dysfunctions linking obesity to insulin resistance and type 2 diabetes. Nat. Rev. Mol. Cell Biol. 2008, 9:367-377.
6. Omori K., et al. Overview of PDEs and their regulation. Circ. Res. 2007, 100:309-327.
7. Manganiello V. Cyclic nucleotide phosphodiesterase 5 and sildenafil: promises realized. Mol. Pharmacol. 2003, 63:1209-1211.
8. Corbin J.D., et al. High lung PDE5: A strong basis for treating pulmonary hypertension with PDE5 inhibitors. Biochem. Biophys. Res. Commun. 2005, 334:930-938.
9. Hemmrich K., et al. Nitric oxide and downstream second messenger cGMP and cAMP enhance adipogenesis in primary human preadipocytes. Cytotherapy 2010, 12:547-553.
10. Lafontan M., et al. Control of lipolysis by natriuretic peptides and cyclic GMP. Trends Endocrinol. Metab. 2008, 19:130-137.
11. Elks M.L., et al. Selective effects of phosphodiesterase inhibitors on different phosphodiesterases, adenosine 3',5'-monophosphate metabolism, and lipolysis in 3T3-L1 adipocytes. Endocrinology 1984, 115:1262-1268.
12. Moro C., et al. Phosphodiesterase-5A and neutral endopeptidase activities in human adipocytes do not control atrial natriuretic peptide-mediated lipolysis. Br. J. Pharmacol. 2007, 152:1102-1110.
13. Aversa A., et al. Exposure to phosphodiesterase type 5 inhibitors stimulates aromatase expression in human adipocytes in vitro. J. Sex Med. 2011, 8:696-704.
14. Makhlouf A., et al. Phosphodiesterase 11: a brief review of structure, expression and function. Int. J. Impot. Res. 2006, 18:501-509.
15. Zhang X., et al. Sildenafil promotes adipogenesis through a PKG pathway. Biochem. Biophys. Res. Commun. 2010, 396:1054-1059.
16. Kitamura T., et al. Insulin-induced phosphorylation and activation of cyclic nucleotide phosphodiesterase 3B by the serine-threonine kinase Akt. Mol. Cell Biol. 1999, 19:6286-6296.
17. Yang D.C., et al. cAMP/PKA regulates osteogenesis, adipogenesis and ratio of RANKL/OPG mRNA expression in mesenchymal stem cells by suppressing leptin. PLoS ONE 2008, 3:e1540.
18. Reusch J.E., et al. CREB activation induces adipogenesis in 3T3-L1 cells. Mol. Cell Biol. 2000, 20:1008-1020.
19. Gudi T., et al. NO activation of fos promoter elements requires nuclear translocation of G-kinase I and CREB phosphorylation but is independent of MAP kinase activation. Oncogene 2000, 19:6324-6333.
20. Pilz R.B., et al. Regulation of gene expression by cyclic GMP. Circ. Res. 2003, 93:1034-1046.
21. Haas B., et al. Protein kinase G controls brown fat cell differentiation and mitochondrial biogenesis. Sci. Signal. 2009, 2:ra78.
22. Nishikimi T., et al. Stimulatory and inhibitory regulation of lipolysis by the NPR-A/cGMP/PKG and NPR-C/G(i) pathways in rat cultured adipocytes. Regul. Pept. 2009, 153:56-63.
23. Cinti S. Reversible physiological transdifferentiation in the adipose organ. Proc. Nutr. Soc. 2009, 68:340-349.
24. Amano M., et al. Rho-kinase/ROCK: a key regulator of the cytoskeleton and cell polarity. Cytoskeleton (Hoboken) 2010, 67:545-554.
25. Loirand G., et al. Rho kinases in cardiovascular physiology and pathophysiology. Circ. Res. 2006, 98:322-334.
26. Yan H., et al. Nitric oxide promotes differentiation of rat white preadipocytes in culture. J. Lipid Res. 2002, 43:2123-2129.
27. Nisoli E., et al. Effects of nitric oxide on proliferation and differentiation of rat brown adipocytes in primary cultures. Br. J. Pharmacol. 1998, 125:888-894.
28. Vaandrager A.B., et al. Signalling by cGMP-dependent protein kinases. Mol. Cell Biochem. 1996, 157:23-30.
29. Ross S.E., et al. Inhibition of adipogenesis by Wnt signaling. Science 2000, 289:950-953.
30. Kwon I.K., et al. PKG inhibits TCF signaling in colon cancer cells by blocking beta-catenin expression and activating FOXO4. Oncogene 2010, 29:3423-3434.
31. Zhu J., et al. Effects of FoxO4 overexpression on cholesterol biosynthesis, triacylglycerol accumulation, and glucose uptake. J. Lipid Res. 2010, 51:1312-1324.
32. Aouadi M., et al. p38MAP Kinase activity is required for human primary adipocyte differentiation. FEBS Lett. 2007, 581:5591-5596.
33. Ciani E., et al. Nitric oxide regulates cGMP-dependent cAMP-responsive element binding protein phosphorylation and Bcl-2 expression in cerebellar neurons: implication for a survival role of nitric oxide. J. Neurochem. 2002, 82:1282-1289.
34. Lu Y.F., et al. Nitric oxide signaling contributes to late-phase LTP and CREB phosphorylation in the hippocampus. J. Neurosci. 1999, 19:10250-10261.
35. LaPensee C.R., et al. Insulin stimulates interleukin-6 expression and release in LS14 human adipocytes through multiple signaling pathways. Endocrinology 2008, 149:5415-5422.
36. Wilson-Fritch L., et al. Mitochondrial biogenesis and remodeling during adipogenesis and in response to the insulin sensitizer rosiglitazone. Mol. Cell Biol. 2003, 23:1085-1094.
37. Zhang H.H., et al. Insulin stimulates adipogenesis through the Akt-TSC2-mTORC1 pathway. PLoS ONE 2009, 4:e6189.
38. Huang S., et al. The GLUT4 glucose transporter. Cell. Metab. 2007, 5:237-252.
39. Ishiki M., et al. Minireview: recent developments in the regulation of glucose transporter-4 traffic: new signals, locations, and partners. Endocrinology 2005, 146:5071-5078.
40. Foster L.J., et al. Mechanism and regulation of GLUT-4 vesicle fusion in muscle and fat cells. Am. J. Physiol. Cell Physiol. 2000, 279:C877-C890.
41. Francis S.H., et al. cGMP-dependent protein kinases and cGMP phosphodiesterases in nitric oxide and cGMP action. Pharmacol. Rev. 2010, 62:525-563.
42. Bergandi L., et al. Insulin stimulates glucose transport via nitric oxide/cyclic GMP pathway in human vascular smooth muscle cells. Arterioscler. Thromb. Vasc. Biol. 2003, 23:2215-2221.
43. Mammi C., et al. Sildenafil reduces insulin-resistance in human endothelial cells. PLoS ONE 2011, 6:e14542.
44. Engeli S., et al. Regulation of the nitric oxide system in human adipose tissue. J. Lipid Res. 2004, 45:1640-1648.
45. Nikolic D.M., et al. Overexpression of constitutively active PKG-I protects female, but not male mice from diet-induced obesity. Obesity (Silver Spring) 2011, 19:784-791.
46. Kan W.H., et al. Estrogen ameliorates trauma-hemorrhage-induced lung injury via endothelial nitric oxide synthase-dependent activation of protein kinase G. Ann. Surg. 2008, 248:294-302.
47. Ayala J.E., et al. Chronic treatment with sildenafil improves energy balance and insulin action in high fat-fed conscious mice. Diabetes 2007, 56:1025-1033.
48. Kolditz C.I., et al. Adipose tissue lipolysis. Curr. Opin. Clin. Nutr. Metab. Care 2010, 13:377-381.
49. Langin D., et al. Importance of TNFalpha and neutral lipases in human adipose tissue lipolysis. Trends Endocrinol. Metab. 2006, 17:314-320.
50. Sengenes C., et al. Natriuretic peptide-dependent lipolysis in fat cells is a primate specificity. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2002, 283:R257-R265.
51. Caprio M., et al. PDE5 in human adipose tissue: site specific expression and role in adipocyte function. J. Endocrinol. Invest. 2010, 33(suppl. to No. 4):46.
52. Wang T.J., et al. Impact of obesity on plasma natriuretic peptide levels. Circulation 2004, 109:594-600.
53. Rubattu S., et al. Natriuretic peptides: an update on bioactivity, potential therapeutic use, and implication in cardiovascular diseases. Am. J. Hypertens. 2008, 21:733-741.
54. Tsukamoto O., et al. Natriuretic peptides enhance the production of adiponectin in human adipocytes and in patients with chronic heart failure. J. Am. Coll. Cardiol. 2009, 53:2070-2077.
55. Phillips S.A., et al. Mechanisms of adiponectin regulation and use as a pharmacological target. Curr. Opin. Pharmacol. 2010, 10:676-683.
56. Jones M.E., et al. Estrogen and adiposity - utilizing models of aromatase deficiency to explore the relationship. J. Steroid Biochem. Mol. Biol. 2007, 106:3-7.
57. McInnes K.J., et al. Characterisation of aromatase expression in the human adipocyte cell line SGBS. Breast Cancer Res. Treat. 2008, 112:429-435.
58. Zhao Y., et al. Transcriptional regulation of CYP19 gene (aromatase) expression in adipose stromal cells in primary culture. J. Steroid Biochem. Mol. Biol. 1997, 61:203-210.
59. Sofi M., et al. Role of CRE-binding protein (CREB) in aromatase expression in breast adipose. Breast Cancer Res. Treat. 2003, 79:399-407.
60. Jones M.E., et al. Aromatase-deficient (ArKO) mice have a phenotype of increased adiposity. Proc. Natl. Acad. Sci. U.S.A. 2000, 97:12735-12740.
61. Mendelsohn M.E., et al. Hormonal regulation of normal vascular tone in males. Circ. Res. 2003, 93:1142-1145.
62. Miller A.P., et al. Aged rats lose vasoprotective and anti-inflammatory actions of estrogen in injured arteries. Menopause 2007, 14:251-260.
63. Crandall D.L., et al. Identification of estrogen receptor beta RNA in human breast and abdominal subcutaneous adipose tissue. Biochem. Biophys. Res. Commun. 1998, 248:523-526.
64. Heine P.A., et al. Increased adipose tissue in male and female estrogen receptor-alpha knockout mice. Proc. Natl. Acad. Sci. U.S.A. 2000, 97:12729-12734.
65. Guazzi M. Clinical use of phosphodiesterase-5 inhibitors in chronic heart failure. Circ. Heart Fail. 2008, 1:272-280.
66. Kumar P., et al. Phosphodiesterase 5 inhibition in heart failure: mechanisms and clinical implications. Nat. Rev. Cardiol. 2009, 6:349-355.
67. Nagendran J., et al. Phosphodiesterase type 5 is highly expressed in the hypertrophied human right ventricle, and acute inhibition of phosphodiesterase type 5 improves contractility. Circulation 2007, 116:238-248.
68. Beavo J.A., et al. Cyclic nucleotide research - still expanding after half a century. Nat. Rev. Mol. Cell Biol. 2002, 3:710-718.
69. Jiang H., et al. Direct evidence for cross-activation of cGMP-dependent protein kinase by cAMP in pig coronary arteries. J. Biol. Chem. 1992, 267:1015-1019.
70. - transport by heat-stable enterotoxin: activation of cAMP-dependent protein kinase by cGMP. Am. J. Physiol. 1992, 263:C607-615.
71. Shabb J.B., et al. One amino acid change produces a high affinity cGMP-binding site in cAMP-dependent protein kinase. J. Biol. Chem. 1990, 265:16031-16034.
72. Foster J.L., et al. Autophosphorylation of cGMP-dependent protein kinase. J. Biol. Chem. 1981, 256:5029-5036.